NEW YORK (GenomeWeb News) – GNS Healthcare will work with researchers at Dana-Farber Cancer Institute and Mount Sinai School of Medicine to create computer models of multiple myeloma for use in developing new therapies, the data analytics firm said today.

GNS said it will use its REFS (reverse engineering and forward simulation) platform to create network models from next-generation genome sequencing, proteomic, and clinical data.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.